Royal Bank Of Canada Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock

Posted by Stephan Jacobs on Feb 4th, 2026

Amgen (NASDAQ:AMGN – Get Free Report) had its price target upped by Royal Bank Of Canada from $335.00 to $360.00 in a report issued on Wednesday,MarketScreener reports. The brokerage presently has an “outperform” rating on the medical research company’s stock. Royal Bank Of Canada’s price objective points to a potential upside of 4.15% from the stock’s current price.

Several other research firms have also recently issued reports on AMGN. Deutsche Bank Aktiengesellschaft increased their price target on shares of Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a report on Tuesday, November 11th. Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Oppenheimer set a $400.00 price objective on Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Wall Street Zen raised Amgen from a “buy” rating to a “strong-buy” rating in a report on Monday, December 15th. Finally, Cantor Fitzgerald upped their price target on shares of Amgen from $305.00 to $315.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $344.83.

View Our Latest Stock Analysis on AMGN

Amgen Stock Performance

Shares of Amgen stock opened at $345.66 on Wednesday. The stock has a market capitalization of $186.13 billion, a price-to-earnings ratio of 27.18, a PEG ratio of 3.03 and a beta of 0.46. The firm’s fifty day simple moving average is $332.76 and its 200-day simple moving average is $310.04. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. Amgen has a 12 month low of $261.43 and a 12 month high of $353.25.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period last year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts forecast that Amgen will post 20.62 earnings per share for the current year.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 10,908 shares of company stock valued at $3,674,966. Company insiders own 0.69% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Laurel Wealth Advisors LLC lifted its stake in shares of Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after acquiring an additional 6,676,575 shares during the period. Norges Bank bought a new stake in Amgen in the second quarter worth about $1,663,726,000. Capital World Investors lifted its holdings in shares of Amgen by 11.5% during the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after purchasing an additional 1,935,876 shares during the last quarter. Vanguard Group Inc. raised its holdings in Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after buying an additional 961,975 shares during the period. Finally, National Bank of Canada FI raised its holdings in shares of Amgen by 237.7% during the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after acquiring an additional 863,216 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Q4 results beat Street estimates — Amgen reported $5.29 EPS on $9.87B revenue, ahead of expectations, and cited volume growth and a lower tax rate as drivers of the upside; these beats support the company’s outlook and were the main near-term bullish catalyst. Amgen quarterly results beat Street estimates on higher sales, lower tax rate (Reuters)
Positive Sentiment: Analyst upgrade/price-target lift — Leerink Partners raised its price target to $355 and kept an outperform view, signaling bullish conviction from some buy‑side analysts and providing upside to the stock. Leerink raises AMGN price target to $355 (Benzinga)
Positive Sentiment: Pipeline and product momentum — Coverage notes highlight product-portfolio expansion and pipeline progress (new launches contributing to double‑digit revenue/EPS growth for 2025), which underpin management’s outlook. AMGN Q4 Deep Dive: Product Portfolio Expansion and Pipeline Progress Drive Outlook (Yahoo)
Neutral Sentiment: Mixed analyst views — Some publications note divergent analyst opinions on valuation and near‑term risks, producing a mixed consensus that can limit a stronger rally. Analysts’ Opinions Are Mixed on These Healthcare Stocks (Globe and Mail)
Negative Sentiment: Regulatory and LOE concerns — Analysis flags regulatory tensions around Tavneos and the challenge of mitigating loss‑of‑exclusivity (LOE) impacts, which increase execution risk and could pressure future growth if approvals or launches are delayed. Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge (Seeking Alpha)
Negative Sentiment: Analyst caution on legacy erosion and execution — Some analysts (Citi/TipRanks) maintained or reiterated hold ratings, citing legacy-product erosion and execution risks that justify a more cautious stance and likely contributed to the stock pulling back. Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks (TipRanks)

Amgen Company Profile

(Get Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.